Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease
23/07/2026 21:57
BRIEF-Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease July 23 (Reuters) - Prime Medicine, Inc PRME.O:
PRIME MEDICINE ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR PM577A IN H1069Q-MUTATED WILSON DISEASE
PRIME MEDICINE, - PHASE 1/2 TRIAL FOR PM577A EXPECTED TO START IN H2 2026 WITH INITIAL DATA IN 2027
Source text: ID:nGNX554FZ4
Further company coverage: PRME.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Prime Medicine
See all newsBrief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Prime Medicine Q2 net loss narrows on lower expenses
Brief: Prime Medicine, Inc. Q2 EPS USD -0.24
Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease